Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 216

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis

Open access
Brandl, Katharina, Hartmann, Phillipp, Jih, Lily J., Pizzo, Donald P., Argemi, Josepmaria, Ventura-Cots, Meritxell, Coulter, Sally, Liddle, Christopher, Ling, Lei, Rossi, Stephen J., DePaoli, Alex M., Loomba, Rohit, Mehal, Wajahat Z., Fouts, Derrick E., Lucey, Michael R., Bosques-Padilla, Francisco, Mathurin, Philippe, Louvet, Alexander, Garcia-Tsao, Guadalupe, Verna, Elizabeth C., Abraldes, Juan G., Brown, Robert S., Vargas, Victor, Altamirano, Jose, Caballería, Juan, Shawcross, Debbie, Stärkel, Peter, Ho, Samuel B., Bataller, Ramon, Schnabl, Bernd · 2018 · Journal of Hepatology

Abstract

Background & Aims The degree of cholestasis is an important disease driver in alcoholic hepatitis, a severe clinical condition that needs new biomarkers and targeted therapies. The mechanisms and biomarkers linked to cholestasis are largely unknown. Methods Here, we analyzed a well characterized cohort of patients with alcoholic hepatitis and correlated clinical and histological parameters and outcomes with serum bile acids and fibroblast growth factor 19 (FGF19), a major regulator of bile acids synthesis. Results We found that total and conjugated bile acids were significantly increased in patients with alcoholic hepatitis compared with controls. Serum FGF19 levels were strongly increased and gene expression of FGF19 was induced in biliary epithelial cells and ductular cells of patients with alcoholic hepatitis. De novo bile acid synthesis (CYP7A1 gene expression and C4 serum levels) was significantly decreased in alcoholic hepatitis patients. Importantly, total and conjugated bile acids correlated positively with FGF19 and with disease severity (MELD). FGF19 correlated best with conjugated cholic acid (CA), and MELD best with taurine-conjugated chenodeoxycholic acid (T-CDCA). Univariate analysis demonstrated significant associations between FGF19 and bilirubin as well as gamma-glutamyl-transferase (GGT), and negative correlations between FGF19 and fibrosis stage as well as polymorphonuclear leukocyte (PMN) infiltration in all alcoholic hepatitis patients. Conclusion Serum FGF19 and bile acids are significantly increased in patients with alcoholic hepatitis, while de novo bile acid synthesis is suppressed. Modulation of bile acid metabolism or signaling could represent a promising target for treatment of alcoholic hepatitis in humans. Understanding underlying mechanisms that drive alcoholic hepatitis is important for the development of new biomarkers and targeted therapies. Here we describe a molecule that is increased in patients with alcoholic hepatitis and modulating this pathway might lead to promising targets for the treatment of alcoholic hepatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.03.031

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 216

Metadata

Authors
Brandl, K., Hartmann, P., Jih, L. J., Pizzo, D. P., Argemi, J., Ventura-Cots, M., Coulter, S., Liddle, C., Ling, L., Rossi, S. J., DePaoli, A. M., Loomba, R., Mehal, W. Z., Fouts, D. E., Lucey, M. R., Bosques-Padilla, F., Mathurin, P., Louvet, A., Garcia-Tsao, G., Verna, E. C., Abraldes, J. G., Brown, R. S., Vargas, V., Altamirano, J., Caballería, J., Shawcross, D., Stärkel, P., Ho, S. B., Bataller, R., & Schnabl, B.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-08
Volume
69
Issue
2
Pages
396-405
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2797379250
Cited by
216
References
3
FWCI
14.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.